Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

Qian-Ya Fan; Xiao-Dong Zhang; Ze-Di Hu; Shi-Shi Huang; Shi-Guo Zhu; Cai-Ping Chen; Xiong Zhang; Jian-Yong Wang

doi:10.3389/fneur.2022.961758

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

Front Neurol. 2022 Sep 30:13:961758. doi: 10.3389/fneur.2022.961758. eCollection 2022.

Authors

Qian-Ya Fan¹, Xiao-Dong Zhang², Ze-Di Hu³, Shi-Shi Huang³, Shi-Guo Zhu³, Cai-Ping Chen⁴, Xiong Zhang³, Jian-Yong Wang³

Affiliations

¹ Department of Neurology, The First People's Hospital of Jiande, Hangzhou, China.
² Department of Cerebral Surgery, The First People's Hospital of Jiande, Hangzhou, China.
³ Institute of Geriatric Neurology, Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
⁴ Central Blood Bank of Jiande, Hangzhou, China.

Abstract

Introduction: Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period.

Case presentation: We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.

Conclusion: The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.

Keywords: Parkinson's disease; amantadine; blepharospasm; dyskinesia; peak-dose dyskinesia.

Publication types

Case Reports